Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.

ABSTRACT: In this post hoc analysis, we assessed romosozumab efficacy and safety in European patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab for a further 24 months, resulted in early and sustained risk reduction for major fracture categories, associated with large gains in bone mineral density.

Introduction

In the multinational FRAME phase 3 trial of romosozumab in postmenopausal women with osteoporosis, marked differences between clinical and non-vertebral fracture outcomes were observed among patients from Central and Southern America versus rest of world. This post hoc analysis assessed romosozumab efficacy and safety in European patients enrolled in the FRAME trial and extension study.

Methods

In FRAME (NCT01575834), patients were randomi

SUBMITTER: Langdahl B 

PROVIDER: S-EPMC9652294 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature